Jump to content

Glyclopyramide

From Wikipedia, the free encyclopedia
Glyclopyramide
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-chloro-N-[(pyrrolidin-1-ylamino)carbonyl]benzenesulfonamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H14ClN3O3S
Molar mass303.76 g·mol−1
3D model (JSmol)
  • C1CCN(C1)NC(=O)NS(=O)(=O)C2=CC=C(C=C2)Cl
  • InChI=1S/C11H14ClN3O3S/c12-9-3-5-10(6-4-9)19(17,18)14-11(16)13-15-7-1-2-8-15/h3-6H,1-2,7-8H2,(H2,13,14,16) ☒N
  • Key:HNSCCNJWTJUGNQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Glyclopyramide (INN, marketed under the tradename Deamelin-S) is a sulfonylurea drug used in the treatment of diabetes. It has been marketed in Japan since 1965.

It is classified as second generation.[1]

References

[edit]
  1. ^ Ozawa H, Murai Y, Ozawa T (2003). "[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus]". Yakugaku Zasshi (in Japanese). 38 (1): 11–27. PMID 14570054.
[edit]